髂静脉支架联合大隐静脉高位结扎/腔内激光治疗CEAP 4-6级慢性静脉疾病
本研究为回顾性队列研究,比较髂静脉支架置入单用(42例)与联合大隐静脉高位结扎/腔内激光(29例)治疗伴严重髂静脉狭窄的下肢慢性静脉疾病(CVD)的疗效。中位随访15个月显示,在CEAP临床分级≥4级的患者中,联合治疗显著改善生活质量、静脉临床严重程度评分、疼痛、淤积性皮炎和静脉溃疡愈合率。
要点
- 非血栓性髂静脉压迫综合征(NIVCS)在838例患者中占11.7%,不应忽视。
- CEAP≥4级患者联合治疗组VCSS降低11.89±1.82,显著优于单用支架组的4.64±1.72(P<.01)。
- 联合治疗组淤积性皮炎缓解率90.5%、静脉溃疡愈合率87.5%,均显著高于单用支架组(P<.05)。
核心结论
- 对于NIVCS合并晚期CVD(CEAP临床分级≥4级)的患者,支架联合大隐静脉高位结扎/腔内激光治疗在短期随访中有效。
研究设计与样本
- 回顾性队列研究,纳入伴严重髂静脉狭窄的下肢CVD患者,分为支架单用组(n=42)和支架联合大隐静脉高位结扎/腔内激光组(n=29)。
- 中位随访15个月(范围6-25个月),采用静脉临床严重程度评分(VCSS)、视觉模拟评分(VAS)和慢性静脉疾病生活质量问卷(CIVIQ)评估。
主要发现
- NIVCS患病率为11.7%(98/838例),技术成功率100%,无严重并发症。
- NIVCS患者平均随访15.0个月(范围6-25个月)的通畅率为94.4%。
- CEAP<4级患者中,除静脉曲张消失外,两组各项参数改善相似;CEAP≥4级患者中,联合治疗显著改善生活质量。
- VCSS降低值:单用支架组4.64±1.72 vs 联合治疗组11.89±1.82(P<.01)。
- VAS疼痛评分:单用支架组从4.41降至2.52(P<.05),联合治疗组从4.71降至0.53(P<.01)。
临床怎么用
- 对NIVCS合并CEAP≥4级CVD的患者,可考虑在髂静脉支架基础上联合大隐静脉高位结扎/腔内激光治疗以改善生活质量及皮肤/溃疡结局。
局限性
- 本研究为回顾性队列研究,样本量有限(共71例),随访时间较短(中位15个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lower limb chronic venous disease (CVD), resulting from iliac vein compression syndrome (IVCS), manifests as a series of symptoms ranging from varicose veins to venous ulcerations. Stent implantation has been considered an effective treatment method; however, the management of CVD has rarely been reported. In the present study, we evaluated the treatment and outcomes of patients with CVD. METHODS: We performed a retrospective cohort study of patients with severe iliac vein stenosis with lower limb CVD. The patients were divided into two groups: group 1 had received stenting alone (n = 42), and group 2 had received stenting and high ligation/endovenous laser treatment (n = 29). We evaluated the clinical outcomes using the Venous Clinical Severity Score and visual analog scale, and assessed the quality of life (QoL) using the Chronic Venous Disease QoL questionnaire at a median follow-up point of 15 months (range, 6-25 months). RESULTS: In our cohort, the prevalence rate of nonthrombotic IVCS (NIVCS) was 11.7% (98 of 838 patients). The technical success rate was 100%, without severe complications. During the study period, three group 1 patients and two group 2 patients were lost to follow-up. The overall patency rate in the patients with NIVCS during a mean follow-up period of 15.0 months (range, 6-25 months) was 94.4%. For patients with a Clinical, Etiology, Anatomy, Pathophysiology (CEAP) clinical class of <4, all parameters showed similar improvements in the two groups, except for the disappearance of varicose veins. However, in patients with a CEAP clinical class of ≥4, the combination therapy significantly improved their QoL. The Venous Clinical Severity Score reduction was 4.64 ± 1.72 in group 1 and 11.89 ± 1.82 in group 2 (P < .01). Pain, scored using the visual analog scale, demonstrated a decrease from 4.41 to 2.52 (P < .05) in group 1 and 4.71 to 0.53 (P < .01) in group 2. The relief rate of stasis dermatitis in groups 1 and 2 was 26.9% and 90.5%, respectively (P < .05), and the venous ulceration healing rate was 16.7% and 87.5%, respectively (P < .05). CONCLUSIONS: The prevalence of NIVCS should not be overlooked. The proposed combination treatment is an effective therapeutic strategy for patients with NIVCS and advanced CVD (CEAP clinical class, ≥4) during short-term follow-up.
引用
- Guo Z, Li X, Wang T, et al. Effectiveness of iliac vein stenting combined with high ligation/endovenous laser treatment of the great saphenous veins in patients with Clinical, Etiology, Anatomy, Pathophysiology class 4 to 6 chronic venous disease. J Vasc Surg Venous Lymphat Disord. 2019. PMID: 31699666. doi:10.1016/j.jvsv.2019.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。